HTG Molecular Diagnostics Inc (NASDAQ:HTGM) shares fell 2.9% on Thursday . The stock traded as low as $2.30 and last traded at $2.71, with a volume of 54,989 shares. The stock had previously closed at $2.79.

Several brokerages recently weighed in on HTGM. Canaccord Genuity reaffirmed a “buy” rating and issued a $6.00 target price on shares of HTG Molecular Diagnostics in a report on Friday, May 13th. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a report on Monday, April 11th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $5.00 target price (down previously from $10.00) on shares of HTG Molecular Diagnostics in a report on Monday, March 28th.

The company’s market capitalization is $18.99 million. The company’s 50-day moving average is $2.80 and its 200-day moving average is $3.03.

HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its quarterly earnings results on Thursday, May 12th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.83) by $0.19. On average, analysts forecast that HTG Molecular Diagnostics Inc will post ($3.91) earnings per share for the current fiscal year.

HTG Molecular Diagnostics, Inc is a provider of instruments and reagents for molecular profiling applications. The Company has developed and markets a technology platform for the routine use of complex molecular profiling. The Company’s HTG Edge platform, consisting of instrumentation, including HTG Edge and HTG EdgeSeq systems, consumables and software analytics, is used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.